Trump’s Move on Cannabis Schedule I Reclassification Could Accelerate Research
Cannabis Schedule I reclassification research impact could remove significant regulatory barriers limiting clinical studies. This change may accelerate high-quality research on cannabis for medical use. The reclassification promises to open new…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The temporary scheduling of 2-fluorodeschloroketamine reflects regulatory efforts to control emerging synthetic ketamine analogs. This DEA action addresses public health concerns related to novel psychoactive substances. Clinicians should stay informed…
Schedules of Controlled Substances: DEA Scheduling of Benzodiazepine Analogs in 2026
The DEA scheduling benzodiazepine analogs 2026 update places five synthetic benzodiazepines into Schedule I, addressing significant regulatory gaps. This action impacts clinical management and toxicology screening. Awareness of these changes is crucial…